Semaglutide 5mg
Size: 5mg | 99% Purity
M.Wt: 4113.58
Formula: C187H291N45O59
Solubility: H2O
Purity: >99%
Storage: -20°C / 3 years
Half life: Not established
CAS No.: 910463-68-2
| Available sizes | 0.05kg |
|---|---|
| Purity (HPLC) | >99% |
| Molecular weight | 4113.58 g/mol |
| Molecular formula | C187H291N45O59 |
| CAS number | 910463-68-2 |
| Synonyms | Ozempic Active Compound, Wegovy Active Compound, NNC9204-0294, OG217SC |
| Solubility | H2O |
| Storage | -20°C / 3 years |
| Half-life | Not established |
Peptide sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH2HPLC and MS verified by UKAS-accredited laboratories.
Royal Mail 24 and DPD Next Day options.
COA and batch number on every vial.
Description
Size: 5mg | 99% Purity
M.Wt: 4113.58
Formula: C187H291N45O59
Solubility: H2O
Purity: >99%
Storage: -20°C / 3 years
Half life: Not established
CAS No.: 910463-68-2
*(This is a lyophilised powder and will need reconstitution — Sterile Water for reconstitution is supplied separately.)
Reconstitution
For peptides supplied as lyophilised powder, reconstitute in bacteriostatic water or sterile saline at the concentration appropriate to your protocol. Allow the vial to come to room temperature before opening, add solvent slowly down the inside wall (do not directly onto the powder), and gently invert until clear. Do not vortex.
Reconstituted solutions are typically stable at 2–8°C for the durations published in the corresponding peer-reviewed reference. For long-term storage, aliquot and freeze at −20°C; avoid repeated freeze–thaw cycles.
Research literature
Selected peer-reviewed publications from PubMed referencing this compound. Provided for research orientation — not an endorsement of any clinical application. Each citation links to the canonical PubMed record.
-
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA et al. · Molecular metabolism · 2021
PubMed PMID 33068776 -
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.
Sloop KW et al. · Science translational medicine · 2024
PubMed PMID 39693407 -
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Stefanakis K et al. · Metabolism: clinical and experimental · 2024
PubMed PMID 39481534
You may also need
Related compounds
